Key result
The novel antiplatelet agent GT-12 (<100 mumol/L) effectively inhibited surface platelet aggregation and reduced the net rate of individual thrombus growth to zero after 60 seconds of exposure.
Why the study?
Does GT-12 inhibit platelet aggregation and thrombus growth in whole blood on collagen-coated glass?
Population
Whole blood evaluated in a parallel plate flow chamber and epifluorescence video microscopy system on…
Comparison
GT-12 at concentrations <100 mumol/L vs Controls and chlorpromazine
Design
Preclinical
Authors
Loading...
GT-12 merits further preclinical testing; hypothesis-generating and should not yet change practice.
Does GT-12 inhibit platelet aggregation and thrombus growth in whole blood on collagen-coated glass?
GT-12 is a novel antiplatelet agent that effectively inhibits platelet aggregation and thrombus growth in whole blood at low concentrations in an in vitro flow model.
Folie et al. (1988) studied this question. GT-12 vs. Controls and chlorpromazine was evaluated on Surface platelet aggregation and kinetics of thrombus growth. The novel antiplatelet agent GT-12 (<100 mumol/L) effectively inhibited surface platelet aggregation and reduced the net rate of individual thrombus growth to zero after 60 seconds of exposure.
Synapse has enriched one closely related paper. Consider it for comparative context: